Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
2005 2
2007 2
2014 3
2015 2
2016 2
2017 1
2018 1
2019 2
2020 2
2021 5
2022 1
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, Aizenberg D, Wynne AG, Riesmeyer JS, Heine RJ, Wiese RJ; SURPASS-4 Investigators. Del Prato S, et al. Lancet. 2021 Nov 13;398(10313):1811-1824. doi: 10.1016/S0140-6736(21)02188-7. Epub 2021 Oct 18. Lancet. 2021. PMID: 34672967 Clinical Trial.
[COVID-19 pandemic and endocrinopathies].
Mokrysheva NG, Galstyan GR, Kirzhakov MA, Eremkina AK, Pigarova EA, Melnichenko GA. Mokrysheva NG, et al. Among authors: galstyan gr. Probl Endokrinol (Mosk). 2020 Aug 4;66(1):7-13. doi: 10.14341/probl12376. Probl Endokrinol (Mosk). 2020. PMID: 33351308 Review. Russian.
Management of patients with diabetes and obesity in the COVID-19 era: Experiences and learnings from South and East Europe, the Middle East, and Africa.
Giorgino F, Bhana S, Czupryniak L, Dagdelen S, Galstyan GR, Janež A, Lalić N, Nouri N, Rahelić D, Stoian AP, Raz I. Giorgino F, et al. Among authors: galstyan gr. Diabetes Res Clin Pract. 2021 Feb;172:108617. doi: 10.1016/j.diabres.2020.108617. Epub 2020 Dec 10. Diabetes Res Clin Pract. 2021. PMID: 33310175 Free PMC article. Review.
[Resolution on the results of the first working meeting of the Scientific Advisory Board «Actual problems of glycemic variability as a new criterion of glycemic control and safety of diabetes therapy»].
Antsiferov MB, Galstyan GR, Zilov AV, Mayorov AY, Markova TN, Demidov NA, Koteshkova OM, Laptev DN, Vitebskaya AV, Alekseeva YG, Stavtseva SI. Antsiferov MB, et al. Among authors: galstyan gr. Probl Endokrinol (Mosk). 2019 Sep 12;65(3):204-211. doi: 10.14341/probl10197. Probl Endokrinol (Mosk). 2019. PMID: 31566317 Russian.
[Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial].
Arutyunov GP, Lopatin YM, Ametov AS, Ageev FT, Antsiferov MB, Villevalde SV, Vinogradova NG, Galstyan GR, Galyavich AS, Gilyarevskiy SR, Glezer MG, Zhirov IV, Ilyin MV, Lebedeva AI, Nedogoda SM, Salukhov VV, Tarlovskaya EI, Tereshchenko SN, Fomin IV, Khalimov IS, Khasanov NR, Cherkashin DV, Yakushin SS. Arutyunov GP, et al. Among authors: galstyan gr. Ter Arkh. 2021 Dec 15;93(12):1491-1497. doi: 10.26442/00403660.2021.12.201281. Ter Arkh. 2021. PMID: 36286678 Russian.
Lifestyle modification program, LIFE is LIGHT, in patients with type 2 diabetes mellitus and obesity: Results from a 48-week, multicenter, non-randomized, parallel-group, open-label study.
Galstyan GR, Valeeva FV, Motkova SI, Surkova EV, Savelyeva LV, Rudina LM, Ramanathan K, Sokareva E, Bondareva K, Shestakova MV. Galstyan GR, et al. Obes Sci Pract. 2021 Apr 9;7(4):368-378. doi: 10.1002/osp4.502. eCollection 2021 Aug. Obes Sci Pract. 2021. PMID: 34401196 Free PMC article.
26 results